

Research Grade Cendakimab

SKU: GXEL00012 | Assay: Quantitative ELISA (Colorimetric)

The Research Grade Cendakimab (SKU: GXEL00012) is a high-sensitivity quantitative ELISA for the quantitative measurement of Research Grade Cendakimab in Plasma, Serum. The assay covers a detection range of 0.31-5 µg/mL with a sensitivity of 0.156 µg/ml and is read colorimetrically at 450 nm.

Background: Tigatuzumab is the humanized version of the agonistic murine monoclonal antibody TRA-8 that binds to the death receptor 5 and induces apoptosis of human cancer cell lines via the caspase cascade. The combination of tigatuzumab and gemcitabine inhibits tumor growth in murine pancreatic xenografts. This phase 2 trial evaluated the efficacy of tigatuzumab combined with gemcitabine in 62 chemotherapy-naïve patients with histologically or cytologically confirmed unresectable or metastatic pancreatic cancer. Patients received intravenous tigatuzumab (8 mg/kg loading dose followed by 3 mg/kg weekly) and gemcitabine (1000 mg/m²) once weekly for 3 weeks followed by 1 week of rest until progressive disease (PD) or unacceptable toxicity occurred. The primary end point was progression-free survival (PFS) at 16 weeks. Secondary end points included objective response rate (ORR) (complete responses plus partial responses), duration of response, and overall survival (OS). Safety of the combination was also evaluated. Mean duration of treatment was 18.48 weeks for tigatuzumab and 17.73 weeks for gemcitabine. The PFS rate at 16 weeks was 52.5% (95% confidence interval [CI], 39.3-64.1%). The ORR was 13.1%; 28 (45.9%) patients had stable disease and 14 (23%) patients had PD. Median PFS was 3.9 months (95% CI, 2.2-5.4 months). Median OS was 8.2 months (95% CI, 5.1-9.6 months). The most common adverse events related to tigatuzumab were nausea (35.5%), fatigue (32.3%), and peripheral edema (19.4%). Tigatuzumab combined with gemcitabine was well tolerated and may be clinically active for the treatment of chemotherapy-naïve patients with unresectable or metastatic pancreatic cancer.

Specifications

Product Name	Research Grade Cendakimab
SKU	GXEL00012
Accession	O14763
Alternative Names	CS-1008, TRA-8, 918127-53-4
Assay Type	Quantitative
Detection Method	Colorimetric
Sensitivity	0.156 µg/ml
Detection Range	0.31-5 µg/mL
Recovery	80-120%
Sample Types	Plasma, Serum
Storage	2-8°C. See Storage & Stability.
Note	For Research Use Only. Not for diagnostic procedures.

Storage & Stability

The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition. Store at 2-8°C on receipt; avoid repeated freeze-thaw cycles.

Assay Genie Ltd, 25 Windsor Place, Dublin 2, D02 VY42, Ireland | +353 1 563 9720 | www.assaygenie.com | techsupport@assaygenie.com
 Datasheet: <https://store-h68l9z2lnx.mybigcommerce.com/content/Technical%20Manuals/ELISA/GXEL/GXEL00012.pdf> | Version 1.0, 09 July 2026